Segment, Geographical and Other Revenue Information (Tables)

3 Months Ended

Mar. 31, 2022

The following table provides financial information by our reportable business segments along with a reconciliation to consolidated loss before income taxes (in thousands):


	Three Months Ended March 31, 2022						Three Months Ended March 31, 2021
	Performance Enzymes		Novel Biotherapeutics		Total		Performance Enzymes		Novel Biotherapeutics		Total
Revenues:
Product revenue	$	30,690	$	—	$	30,690	$	10,226	$	—	$	10,226
Research and development revenue	2,409		2,241		4,650		4,003		3,803		7,806
Total revenues	33,099		2,241		35,340		14,229		3,803		18,032
Costs and operating expenses:
Cost of product revenue	8,521		—		8,521		4,218		—		4,218
Research and development (1)	6,122		12,346		18,468		6,444		4,605		11,049
Selling, general and administrative (1)	3,541		720		4,261		2,818		600		3,418
Total segment costs and operating expenses	18,184		13,066		31,250		13,480		5,205		18,685
Income (loss) from operations	$	14,915	$	(10,825)	4,090		$	749	$	(1,402)	(653)
Corporate costs (2)					(11,205)						(7,728)
Unallocated depreciation and amortization					(1,232)						(685)
Loss before income taxes					$	(8,347)					$	(9,066)

(1) Research and development expenses and selling, general and administrative expenses exclude depreciation and amortization of finance leases.
(2) Corporate costs include unallocated selling, general and administrative expenses, interest income, and other expense, net.

The following table provides stock-based compensation expense included in income (loss) from operations (in thousands):


	Three Months Ended March 31,
	2022								2021
	Performance Enzymes		Novel Biotherapeutics		Corporate cost		Total		Performance Enzymes		Novel Biotherapeutics		Corporate cost		Total
Stock-based compensation	$	1,487	$	410	$	1,941	$	3,838	$	994	$	238	$	1,455	$	2,687

Schedule of customers that contributed 10% or more of total accounts receivable

Significant Customers

Customers that each accounted for 10% or more of our total revenues were as follows:


	Percentage of Total Revenues for the
	Three Months Ended March 31,
	2022		2021
Customer A	61	%	*
Customer B	*		28	%
Customer C	*		11	%
Customer D	*		10	%
Customer E	*		14	%
* Percentage was less than 10%

Customers that each accounted for 10% or more of accounts receivable balances as of the periods presented as follows:


	Percentage of Accounts Receivables as of
	March 31, 2022		December 31, 2021
Customer A	65	%	62	%

Schedule of revenues by geographical area

Geographic revenues are identified by the location of the customer and consist of the following (in thousands):


	Three Months Ended March 31,
	2022		2021
Revenues:
Americas	$	3,732	$	4,929
EMEA	4,127		6,282
APAC	27,481		6,821
Total revenues	$	35,340	$	18,032

Schedule of long-lived assets by geographical area

Identifiable long-lived assets by location was as follows (in thousands):


	March 31, 2022		December 31, 2021
United States	$	66,386	$	65,457

Schedule of intangible assets and goodwill

Identifiable goodwill by reporting unit was as follows (in thousands):


	As of March 31, 2022 and December 31, 2021
	Performance Enzymes		Novel Biotherapeutics		Total
Goodwill	$	2,463	$	778	$	3,241